Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Taxes (2016 - 2025)

Historic Change in Taxes for Enanta Pharmaceuticals (ENTA) over the last 12 years, with Q2 2025 value amounting to $31.9 million.

  • Enanta Pharmaceuticals' Change in Taxes rose 743490.57% to $31.9 million in Q2 2025 from the same period last year, while for Dec 2025 it was $33.3 million, marking a year-over-year increase of 459577.46%. This contributed to the annual value of $33.8 million for FY2025, which is 329547.74% up from last year.
  • As of Q2 2025, Enanta Pharmaceuticals' Change in Taxes stood at $31.9 million, which was up 743490.57% from $1.4 million recorded in Q1 2025.
  • Enanta Pharmaceuticals' Change in Taxes' 5-year high stood at $31.9 million during Q2 2025, with a 5-year trough of -$8.5 million in Q4 2021.
  • Moreover, its 5-year median value for Change in Taxes was $360500.0 (2024), whereas its average is $3.1 million.
  • The largest annual percentage gain for Enanta Pharmaceuticals' Change in Taxes in the last 5 years was 5097000.0% (2023), contrasted with its biggest fall of 1418500.0% (2023).
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Taxes (Quarter) stood at -$8.5 million in 2021, then soared by 99.82% to -$15000.0 in 2022, then soared by 4966.67% to $730000.0 in 2023, then tumbled by 39.04% to $445000.0 in 2024, then surged by 7079.33% to $31.9 million in 2025.
  • Its Change in Taxes stands at $31.9 million for Q2 2025, versus $1.4 million for Q1 2025 and $445000.0 for Q4 2024.